ValiRx - VAL201 Clinical Trial Update

Dr Suzy Dilly, Chief Executive Officer provides an update on the headline results from the recently completed Phase 1/2 clinical trial of its lead asset VAL201, for the treatment of advanced prostate cancer, held at University College Hospital, London.

Suzanne Dilly
Chief Executive Officer

Company Events - VALIRX PLC